198 related articles for article (PubMed ID: 11743284)
21. Prostate cancer detection by prostate-specific antigen-related parameters.
Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
[TBL] [Abstract][Full Text] [Related]
25. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA.
Morgan TO; McLeod DG; Leifer ES; Moul JW; Murphy GP
Prostate Suppl; 1996; 7():58-63. PubMed ID: 8950365
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
28. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.
Stamey TA; Yemoto CE
J Urol; 2000 Jan; 163(1):119-26. PubMed ID: 10604328
[TBL] [Abstract][Full Text] [Related]
29. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
[TBL] [Abstract][Full Text] [Related]
30. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
[TBL] [Abstract][Full Text] [Related]
31. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
Gann PH; Ma J; Catalona WJ; Stampfer MJ
J Urol; 2002 Jun; 167(6):2427-34. PubMed ID: 11992051
[TBL] [Abstract][Full Text] [Related]
32. [Clinical usefulness of free PSA/total PSA ratio in the early diagnosis of prostatic cancer].
Laguna Pes MP; Guinda Sevillano C; Zazo Romojaro A; Domínguez J; García Luzón A; Borrego Hernando J; Gimeno Collado A
Arch Esp Urol; 2000 May; 53(4):333-41. PubMed ID: 10900763
[TBL] [Abstract][Full Text] [Related]
33. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
34. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.
Park HK; Hong SK; Byun SS; Lee SE
Urology; 2006 Jul; 68(1):85-8. PubMed ID: 16806412
[TBL] [Abstract][Full Text] [Related]
35. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
[TBL] [Abstract][Full Text] [Related]
36. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
[TBL] [Abstract][Full Text] [Related]
37. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
[TBL] [Abstract][Full Text] [Related]
38. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
40. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
Finne P; Zhang WM; Auvinen A; Leinonen J; Määttänen L; Rannikko S; Tammela TL; Stenman UH
J Urol; 2000 Dec; 164(6):1956-60. PubMed ID: 11061890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]